Literature DB >> 30796792

Metabolic and neurobehavioral response following intraovarian administration of autologous activated platelet rich plasma: First qualitative data.

Eric Scott Sills1, Xiang Li1, Natalie S Rickers1, Samuel H Wood2, Gianpiero D Palermo3.   

Abstract

OBJECTIVES: This work assessed sexual and neurobehavioral parameters after ovarian treatment with autologous PRP.
DESIGN: Questionnaire study.
MATERIAL AND METHODS: Patients receiving ovarian PRP injection (n=80) due to low ovarian reserve and/or at least 1 prior failed IVF cycle were sampled. Pre- and post-treatment levels in self-reported daily energy, sleep quality, skin tone/hair thickness/nail growth, cognitive clarity, menstrual pattern, cervical mucus/vaginal lubrication, libido, sexual activity, ability to achieve orgasm, and overall sexual experience were measured.
RESULTS: Mean±SD age and baseline BMI among patients were 45.5±6yrs and 25±5.1kg/m2, respectively. Average weight loss after ovarian PRP was 1kg (p=0.056). After ovarian PRP, superior nail growth, skin tone, and hair thickness was observed by 46.3% of patients [95%CI=35%,57.8%]; the same ratio experienced increased "clarity of thinking" following the procedure. Irregular or absent menses affected 56.3% of patients at enrollment, and menses returned or cyclicity improved in 24.4% after treatment [95%CI=12.9%,39.5%]. Increased post-treatment vaginal lubrication/cervical mucus production was reported by 51.3% of women [95%CI=39.8%, 62.6%] accompanied by increased libido in 55% [95%CI=43.5%,66.2%]. More frequent sexual activity after ovarian PRP was noted from 46.3% of subjects [95%CI=35%, 57.8%] coinciding with a 45% improvement in overall sexual experience before vs. after ovarian PRP [95%CI=33.9%, 56.5%].
CONCLUSION: This investigation is the first to document responses across neurobehavioral and metabolic parameters after ovarian PRP. Injection of PRP-derived growth factors directly into ovarian tissue seems to enable a local signaling milieu favoring development of hormonally active ovarian elements, thus "re-potentiating" low or absent reserve.

Entities:  

Year:  2019        PMID: 30796792

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  6 in total

Review 1.  Novel Approaches in Addressing Ovarian Insufficiency in 2019: Are We There Yet?

Authors:  Konstantinos Sfakianoudis; Anna Rapani; Sokratis Grigoriadis; Dimitra Retsina; Evangelos Maziotis; Petroula Tsioulou; Polina Giannelou; Konstantinos Pantos; Michael Koutsilieris; Nikolaos Vlahos; George Mastorakos; Mara Simopoulou
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 2.  Human Mesenchymal Stem Cell Therapy and Other Novel Treatment Approaches for Premature Ovarian Insufficiency.

Authors:  Mara Ulin; Esra Cetin; Elie Hobeika; Rishi Man Chugh; Hang-Soo Park; Sahar Esfandyari; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2021-05-06       Impact factor: 3.060

Review 3.  Autologous activated platelet-rich plasma injection into adult human ovary tissue: molecular mechanism, analysis, and discussion of reproductive response.

Authors:  E Scott Sills; Samuel H Wood
Journal:  Biosci Rep       Date:  2019-06-04       Impact factor: 3.840

Review 4.  Ovarian recovery via autologous platelet-rich plasma: New benchmarks for condensed cytokine applications to reverse reproductive aging.

Authors:  E Scott Sills
Journal:  Aging Med (Milton)       Date:  2022-02-05

5.  Growth factors, gene activation, and cell recruitment: From intraovarian condensed platelet cytokines to de novo oocyte development.

Authors:  E Scott Sills; Samuel H Wood
Journal:  J Clin Transl Res       Date:  2022-01-25

6.  Appraisal of Experimental Methods to Manage Menopause and Infertility: Intraovarian Platelet-Rich Plasma vs. Condensed Platelet-Derived Cytokines.

Authors:  E Scott Sills; Samuel H Wood
Journal:  Medicina (Kaunas)       Date:  2021-12-21       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.